MX2022003195A - Moleculas de union a pd-l1 que comprenden andamios de la subunidad a de la toxina shiga. - Google Patents
Moleculas de union a pd-l1 que comprenden andamios de la subunidad a de la toxina shiga.Info
- Publication number
- MX2022003195A MX2022003195A MX2022003195A MX2022003195A MX2022003195A MX 2022003195 A MX2022003195 A MX 2022003195A MX 2022003195 A MX2022003195 A MX 2022003195A MX 2022003195 A MX2022003195 A MX 2022003195A MX 2022003195 A MX2022003195 A MX 2022003195A
- Authority
- MX
- Mexico
- Prior art keywords
- binding molecules
- cells
- shiga toxin
- positive tumor
- tumor cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/25—Shigella (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2497—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing N- glycosyl compounds (3.2.2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
En la presente se proporcionan moléculas de unión a PD-L1 que comprenden o se conjugan con una toxina, por ejemplo, un polipéptido derivado de la subunidad A de la toxina Shiga. En algunas modalidades, las moléculas de unión a PD-L1 son citotóxicas. En algunas modalidades, las moléculas de unión a PD-L1 son capaces de suministrar un epítopo de células T CD8+ a una molécula de MHC clase I dentro de una célula PD-L1 positiva. Las moléculas de unión a PD-L1 descritas en el presente documento tienen usos para destruir selectivamente células específicas (por ejemplo, células tumorales PD-L1 positivas y/o células inmunes); para suministrar selectivamente cargas a células específicas (por ejemplo, células tumorales PD-L1 positivas o células inmunes) y como moléculas terapéuticas y/o de diagnóstico para tratar y diagnosticar una variedad de afecciones, incluyendo cánceres y tumores que implican células que expresan PD-L1 (por ejemplo, células tumorales PD-L1 positivas o células inmunes).
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962902243P | 2019-09-18 | 2019-09-18 | |
US201962933197P | 2019-11-08 | 2019-11-08 | |
US202062970610P | 2020-02-05 | 2020-02-05 | |
US202063041288P | 2020-06-19 | 2020-06-19 | |
PCT/US2020/051589 WO2021055816A1 (en) | 2019-09-18 | 2020-09-18 | Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022003195A true MX2022003195A (es) | 2022-04-11 |
Family
ID=74868414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022003195A MX2022003195A (es) | 2019-09-18 | 2020-09-18 | Moleculas de union a pd-l1 que comprenden andamios de la subunidad a de la toxina shiga. |
Country Status (9)
Country | Link |
---|---|
US (1) | US11136395B2 (es) |
EP (1) | EP4031576A1 (es) |
JP (1) | JP2022548078A (es) |
KR (1) | KR20220081977A (es) |
CN (1) | CN114423793A (es) |
AU (1) | AU2020348861A1 (es) |
CA (1) | CA3149621A1 (es) |
IL (1) | IL291402A (es) |
MX (1) | MX2022003195A (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106103489B (zh) | 2014-01-27 | 2020-10-02 | 分子模板公司 | Mhc i类表位递送多肽 |
PT3303373T (pt) | 2015-05-30 | 2020-07-14 | Molecular Templates Inc | Estruturas de subunidade a de toxina shiga desimunizadas e moléculas de direcionamento celular compreendendo as mesmas |
IL302130A (en) | 2016-12-07 | 2023-06-01 | Molecular Templates Inc | Shiga toxin A subunit activator polypeptides, Shiga toxin activator scaffolds and cell-targeting molecules for site-specific conjugation |
AU2018213194B2 (en) * | 2017-01-25 | 2023-01-12 | Molecular Templates, Inc. | Cell-targeting molecules comprising de-immunized, Shiga toxin A Subunit effectors and CD8+ T-cell epitopes |
WO2021055816A1 (en) | 2019-09-18 | 2021-03-25 | Molecular Templates, Inc. | Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds |
EP4262858A1 (en) * | 2020-12-16 | 2023-10-25 | Molecular Templates, Inc. | Clinical methods for use of a pd-l1-binding molecule comprising a shiga toxin effector |
US20220306700A1 (en) * | 2021-03-17 | 2022-09-29 | Molecular Templates, Inc. | Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
RU2139092C1 (ru) | 1993-06-03 | 1999-10-10 | Терапьютик Антибодиз Инк. | Фрагменты антител в терапии |
EP1210424B1 (en) | 1999-08-23 | 2007-02-07 | Dana-Farber Cancer Institute, Inc. | Novel b7-4 molecules and uses therefor |
WO2001039722A2 (en) | 1999-11-30 | 2001-06-07 | Mayo Foundation For Medical Education And Research | B7-h1, a novel immunoregulatory molecule |
US6979564B2 (en) | 2000-10-20 | 2005-12-27 | Millennium Pharmaceuticals, Inc. | 80090, human fucosyltransferase nucleic acid molecules and uses thereof |
WO2003094859A2 (en) | 2002-05-10 | 2003-11-20 | Medimmune, Inc. | Epha2 monoclonal antibodies and methods of use thereof |
CA2559536A1 (en) | 2004-03-26 | 2005-10-06 | Jean Gariepy | Library of toxin mutants, and methods of using same |
EP3428191A1 (en) | 2004-10-06 | 2019-01-16 | Mayo Foundation for Medical Education and Research | B7-h1 and pd-1 in treatment of renal cell carcinoma |
SI1907424T1 (sl) | 2005-07-01 | 2015-12-31 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1) |
US20090156417A1 (en) | 2005-09-26 | 2009-06-18 | Jean Gariepy | Library From Toxin Mutants, And Methods Of Using Same |
EP2115002B1 (en) | 2007-02-02 | 2014-08-20 | Baylor Research Institute | Vaccines based on targeting antigen to dcir expressed an antigen-presenting cells |
JP5374360B2 (ja) | 2007-02-27 | 2013-12-25 | 中外製薬株式会社 | 抗grp78抗体を有効成分として含む医薬組成物 |
US7887801B2 (en) | 2007-07-13 | 2011-02-15 | Topotarget Germany Ag | Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins |
DK2342226T3 (en) | 2008-09-26 | 2016-09-26 | Dana Farber Cancer Inst Inc | HUMAN ANTI-PD-1, PD-L1 AND PD-L2 ANTIBODIES AND APPLICATIONS THEREOF |
CN108997498A (zh) | 2008-12-09 | 2018-12-14 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
EP2448966B1 (en) | 2009-07-03 | 2018-11-14 | Avipep Pty Ltd | Immuno-conjugates and methods for producing them |
CN102575542B (zh) | 2009-08-14 | 2014-09-10 | 尤尼弗瑞克斯I有限责任公司 | 用于排气处理装置的安装垫 |
EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
KR101981873B1 (ko) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-pd-l1 항체 및 그의 용도 |
LT2970487T (lt) | 2013-03-12 | 2020-05-11 | Molecular Templates, Inc. | Citotoksiniai baltymai, apimantys tikslinių ląstelių rišimosi sritis ir shiga toksino subvienetų sritis, skirtas selektyviam tam tikrų rūšių ląstelių žudymui |
US20210138076A2 (en) * | 2014-01-27 | 2021-05-13 | Molecular Templates, Inc. | Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes |
US20160177284A1 (en) | 2014-01-27 | 2016-06-23 | Molecular Templates, Inc. | Cell-targeted molecules comprising amino-terminus proximal or amino-terminal shiga toxin a subunit effector regions |
CN106103489B (zh) | 2014-01-27 | 2020-10-02 | 分子模板公司 | Mhc i类表位递送多肽 |
WO2017019623A2 (en) | 2015-07-26 | 2017-02-02 | Molecular Templates, Inc. | Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes |
SI3604333T1 (sl) | 2014-03-11 | 2021-08-31 | Molecular Templates, Inc. | Proteini, ki obsegajo aminoterminalne proksimalne Shiga toksin podenota A efektorske regije in celico-ciljajoče vezavne regije imunogobulinskega tipa, ki so sposobne specifične vezave CD38 |
ES2864124T3 (es) | 2014-03-11 | 2021-10-13 | Molecular Templates Inc | Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal |
US11142584B2 (en) | 2014-03-11 | 2021-10-12 | Molecular Templates, Inc. | CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same |
JP6735237B2 (ja) | 2014-06-11 | 2020-08-05 | モレキュラー テンプレーツ, インク.Molecular Templates, Inc. | プロテアーゼ切断耐性、志賀毒素aサブユニットエフェクターポリペプチド及びそれを含む細胞標的化分子 |
US9535074B2 (en) | 2014-09-08 | 2017-01-03 | Merck Sharp & Dohme Corp. | Immunoassay for soluble PD-L1 |
AU2016215205B2 (en) | 2015-02-05 | 2021-10-21 | Molecular Templates, Inc. | Multivalent CD20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof |
PT3303373T (pt) | 2015-05-30 | 2020-07-14 | Molecular Templates Inc | Estruturas de subunidade a de toxina shiga desimunizadas e moléculas de direcionamento celular compreendendo as mesmas |
UA125898C2 (uk) | 2016-03-04 | 2022-07-06 | Джн Байосайєнсіз, Ллк | Антитіла до tigit |
EP3943508B1 (en) | 2016-03-29 | 2024-01-10 | Board Of Regents, The University Of Texas System | Dual function antibodies specific to glycosylated pd-l1 and methods of use thereof |
AU2017348475B2 (en) | 2016-10-30 | 2024-02-08 | Shanghai Henlius Biotech, Inc. | Anti-PD-L1 antibodies and variants |
IL302130A (en) | 2016-12-07 | 2023-06-01 | Molecular Templates Inc | Shiga toxin A subunit activator polypeptides, Shiga toxin activator scaffolds and cell-targeting molecules for site-specific conjugation |
AU2018213194B2 (en) * | 2017-01-25 | 2023-01-12 | Molecular Templates, Inc. | Cell-targeting molecules comprising de-immunized, Shiga toxin A Subunit effectors and CD8+ T-cell epitopes |
EP3592769B1 (en) | 2017-03-09 | 2024-05-08 | Genmab A/S | Antibodies against pd-l1 |
WO2019059400A1 (ja) | 2017-09-25 | 2019-03-28 | Jsr株式会社 | イムノグロブリン結合タンパク質、及びそれを用いたアフィニティー担体 |
CN111954682A (zh) | 2018-03-19 | 2020-11-17 | 阿贝奥姆公司 | 针对程序性死亡配体1(pd-l1)的高亲和力中和单克隆抗体及其用途 |
WO2020081493A1 (en) | 2018-10-16 | 2020-04-23 | Molecular Templates, Inc. | Pd-l1 binding proteins |
WO2020154475A1 (en) | 2019-01-23 | 2020-07-30 | Molecular Templates, Inc. | Proteins comprising modified immunoglobulin variable light chains |
WO2021055816A1 (en) | 2019-09-18 | 2021-03-25 | Molecular Templates, Inc. | Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds |
-
2020
- 2020-09-18 JP JP2022516301A patent/JP2022548078A/ja active Pending
- 2020-09-18 CN CN202080065242.2A patent/CN114423793A/zh active Pending
- 2020-09-18 AU AU2020348861A patent/AU2020348861A1/en active Pending
- 2020-09-18 CA CA3149621A patent/CA3149621A1/en active Pending
- 2020-09-18 KR KR1020227008153A patent/KR20220081977A/ko unknown
- 2020-09-18 EP EP20786366.3A patent/EP4031576A1/en active Pending
- 2020-09-18 MX MX2022003195A patent/MX2022003195A/es unknown
- 2020-09-21 US US17/027,120 patent/US11136395B2/en active Active
-
2022
- 2022-03-15 IL IL291402A patent/IL291402A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2020348861A1 (en) | 2022-01-27 |
KR20220081977A (ko) | 2022-06-16 |
EP4031576A1 (en) | 2022-07-27 |
US11136395B2 (en) | 2021-10-05 |
US20210079098A1 (en) | 2021-03-18 |
CA3149621A1 (en) | 2021-03-25 |
JP2022548078A (ja) | 2022-11-16 |
IL291402A (en) | 2022-05-01 |
CN114423793A (zh) | 2022-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022003195A (es) | Moleculas de union a pd-l1 que comprenden andamios de la subunidad a de la toxina shiga. | |
CL2020000983A1 (es) | Nuevo péptido de seq id no: 34 para el uso en la inmunoterapia contra el cáncer de pulmón, incluido el cáncer de pulmón amicrocítico y otros tipos de cáncer (divisional de la solicitud no. 201701819) | |
MX2018010167A (es) | Peptidos, combinaciones de peptidos y medicamentos basados en celulas para el uso en la inmunoterapia contra el cancer de vejiga y otros tipos de cancer. | |
WO2019222275A3 (en) | Compositions and methods for tcr reprogramming using inducible fusion proteins | |
PE20180695A1 (es) | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de prostata y otros tipos de cancer | |
PH12018501865A1 (en) | Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers | |
CR20180422A (es) | PÉPTIDOS Y COMBINACIÓN DE PÉPTIDOS NOVEDOSOS PARA SU USO EN INMUNOTERAPIA CONTRA DIVERSOS TUMORES (DIivisional 2017-0522) | |
PE20181164A1 (es) | Nuevos peptidos, combinaciones de peptidos y soportes para el uso en el tratamiento inmunoterapeutico de varios tipos de cancer | |
MX2020008333A (es) | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. | |
CL2021001565A1 (es) | Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores (divisional de la solicitud no. 201702407) | |
CL2020002950A1 (es) | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia y otros tipos de cáncer (divisional de la solicitud 201902878) | |
CL2022000642A1 (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón, incluyendo el nsclc, el sclc y otros cánceres (divisional de la solicitud no. 202000020) | |
AR112331A1 (es) | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón, incluyendo el nsclc, el sclc y otros cánceres | |
WO2022099156A3 (en) | T-cell modulatory polypeptides with conjugation sites and methods of use thereof | |
CL2020001563A1 (es) | Péptidos (seq id no. 64, seq id no. 2 a seq id no. 63, seq id no. 65 a seq id no. 118, y seq id no. 120 a seq id no. 149), combinaciones de péptidos y células para el uso en la inmunoterapia contra el cáncer de vejiga urinaria y otros tipos de cáncer. (divisional solicitud 201802360) | |
CR20190094A (es) | Nuevos péptidos y estructuras de soporte para el uso en la inmunoterapia contra el carcinoma epidermoide de cabeza y cuello y otros de cáncer | |
MX2022007779A (es) | Tratamiento que involucra celulas efectoras inmunitarias modificadas geneticamente para expresar receptores de antigenos. | |
CL2020002857A1 (es) | Nuevos péptidos (seq id no: 146) y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el linfoma no hodgkiniano (lnh) y otros tipos de cáncer (divisional de la solicitud no. 201802096) | |
CL2020002171A1 (es) | Nuevo péptido de seq id no: 12 y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra la leucemia mieloide aguda (lma) y otros tipos de cáncer. (divisional solicitud 201802827) | |
Irfan-maqsood et al. | Engineered Cell Therapy: A Successful Approach to Treat Cancer | |
MX2022000990A (es) | Composiciones y metodos que se dirigen y eliminan celulas madre cancerosas (csc) positivas para alfa-v beta-3 (av?3) y tratan canceres resistentes a farmacos y metastasicos. | |
EA201992860A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл), мелкоклеточного рака легких (мрл) и других видов рака | |
EA202191120A3 (ru) | Пептиды и их комбинации для применения в иммунотерапии раковых заболеваний | |
WO2018183232A3 (en) | Peptides and methods for targeted delivery to tumors | |
CR20170522A (es) | Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores |